Duquesnoy and his collaborators have described
Dabrafenib concentration the sequences of polymorphic amino acid residues in the areas of class I and II HLA molecules, defining functional epitopes and named them eplets  and . This work has resulted in the development of the HLAMatchmaker algorithm , which has been validated by the Eurotransplant group and other centers ,  and . This program has resulted in an increased transplantation rate among highly sensitized patients and a decreased waiting time without compromising graft survival . Such encouraging results support a new paradigm, in which the search for epitope compatibility helps in the search for HLA molecules in the context of transplantation. The HLAMatchmaker algorithm is a powerful tool for determining AMMs. However, despite this benefit it is not universally used. A limiting factor for using this tool is the difficulty in handling and interpretation of often complex results. Selleckchem Omipalisib This is at least partly due to the fact that many of the processing stages must be performed manually, which is not only time-consuming
but it increases the likelihood of errors. We believe that the new paradigm of finding epitope-based compatibility for highly sensitized patients needs to be developed as a user-friendly tool that pinpoints strongly immunogenic as well as weak and non-immunogenic epitopes on the HLA alleles. This would enable to define better the immunological risk of transplantation. With this objective in mind, we have developed the EpHLA software which automates many of the functions of the HLAMatchmaker algorithm . In the presented work we tested the ability of the EpHLA software to determine HLA acceptable mismatches, in a timesaving way, regardless of the user’s background in immunogenetics. As it is the case for every new automation tool,
the EpHLA software was tested for the minimum features that attest to software quality as required by the ISO/IEC 9126-1 International Standard (Information Technology-Software product quality-Part 3-oxoacyl-(acyl-carrier-protein) reductase 1: Quality model; June/1998). The tested features were those that are easily perceptible by the users (e.g., functionality, reliability, usability, and efficiency). Herein, we report an experimental validation aimed at testing the capacity of the EpHLA software in fulfilling these perceptible qualities. To validate the EpHLA software by: (i) successfully categorizing HLA molecules as AMMs or Unacceptable Mismatches (UMMs); and (ii) to show the analysis is done with higher functionality, reliability, usability, and efficiency in comparison to the HLAMatchmaker algorithm in its current Microsoft Excel format. The EpHLA automation software (NIT 000083/2011, INPI Brazil) was developed in the Object Pascal language.